Overview

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have relapsed or refractory acute lymphocytic leukemia.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hannover Medical School
Treatments:
Asparaginase
Cytarabine
Daunorubicin
Dexamethasone
Etoposide
Idarubicin
Ifosfamide
Leucovorin
Levoleucovorin
Methotrexate
Prednisolone
Vindesine
Criteria
DISEASE CHARACTERISTICS: Diagnosis of refractory or relapsed acute lymphocytic leukemia No
isolated extramedullary relapse (e.g., testicular, CNS) Combined extramedullary and bone
marrow relapse allowed No uncontrolled, severe leukemic complications, e.g.: Pneumonia with
hypoxia Shock Cardiac failure Hemorrhage No refractoriness to platelet transfusion No
unaspirable pleural effusions or ascites in patients with first relapse

PATIENT CHARACTERISTICS: Age: 15 to 65 Performance status: Karnofsky 50-100% Life
expectancy: Not specified Hematopoietic: See Disease Characteristics No uncontrolled
bleeding Hepatic: No severe liver disease Renal: Creatinine clearance at least 60 mL/min in
patients with first relapse after a complete remission of 18 months or more Cardiovascular:
See Disease Characteristics No severe cardiac disease (e.g., congestive heart failure,
myocardial infarction within the past 6 months, or severe arrhythmia) Pulmonary: See
Disease Characteristics No severe pulmonary disease that would preclude aggressive
chemotherapy Other: No hypersensitivity to E. coli proteins No severe neurologic or other
disease that would preclude aggressive chemotherapy No severe psychiatric disease or other
condition that would preclude study

PRIOR CONCURRENT THERAPY: Not specified